<DOC>
	<DOCNO>NCT01940094</DOCNO>
	<brief_summary>This study multi-center randomize control trial evaluate effect use low-dose prednisone compare stop prednisone treatment entirely . Participants randomize 1:1 taper prednisone dose 5 mg/day 0 mg/day duration study ( approximately six month ) study endpoint .</brief_summary>
	<brief_title>The Assessment Prednisone In Remission Trial - Centers Excellence Approach</brief_title>
	<detailed_description>Patients granulomatosis polyangiitis ( GPA , Wegener 's ) recruit one Vasculitis Centers Excellence . Participants randomize 1:1 either taper prednisone dose 5 mg/day accord standardized schedule stay 5 mg/day prednisone duration study study endpoint , taper prednisone dose 0 mg/day use standard schedule stay 0 mg/day duration study study endpoint . All study participant follow 6 month ( reach prednisone dose 5 mg/day ) increase prednisone dose ( randomization ) occur , whichever come first . Participants four study visit , screen visit ( visit 1 ) , baseline ( visit 2 ) , month 3 visit ( visit 3 ) month 6 flare visit ( visit 3 ) two follow-up phone call study coordinator randomization month 1 ( randomization 1 month phone call may combine randomization occur month 1 ) . This study project Vasculitis Clinical Research Consortium ( VCRC ) fund National Institutes Health Rare Diseases Clinical Research Network ( RDCRN ) purpose promote vasculitis research . The VCRC major clinical research infrastructure North America study vasculitis , eight VCRC Centers Excellence recruiting study .</detailed_description>
	<mesh_term>Systemic Vasculitis</mesh_term>
	<mesh_term>Granulomatosis Polyangiitis</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<criteria>1 . Established diagnosis granulomatosis polyangiitis ( GPA ) patient need meet least 2 5 classification GPA , least one must criterion e : The modified American College Rheumatology ( ACR ) criterion : A. Nasal oral inflammation , define development painful painless oral ulcer purulent bloody nasal discharge . B. Abnormal chest radiograph , define presence nodule , fix infiltrates , cavity . C. Active urinary sediment , define microscopic hematuria ( &gt; 5 red blood cell per high power field ) red blood cell cast . D. Granulomatosis inflammation biopsy , define histologic change show granulomatous inflammation within wall artery perivascular extravascular area . Note : Pauciimmune glomerulonephritis see kidney biopsy suffice criterion . E. Positive antineutrophil cytoplasmic antibody ( ANCA ) test specific proteinase3 measure enzymelinked immunoassay . Patients myeloperoxidase ( MPO ) positive ANCA negative still eligible study meet criterion felt GPA . 2 . Active disease within prior 12 month ( initial presentation relapse ) time active disease require treatment prednisone &gt; 20 mg/day . 3 . Disease remission time enrollment . 4 . Prednisone dose time enrollment ≥ 5 mg/day ≤ 20 mg/day . 5 . Participant age 18 year great . 6 . If patient take immunosuppressive medication agent prednisone ( maintenance agent ) maintenance agent must stable dose one month prior enrollment plan treat physician change dose ( safety purposes/toxicity ) duration study ( month 6 visit early termination ) . Acceptable maintenance agent include azathioprine , leflunomide , 6mercaptopurine , methotrexate , mycophenolate mofetil , mycophenolate sodium . Patients may trimethoprim/sulfamethoxazole ( TMP/SMX ) use either maintenance agent prophylaxis infection . TMP/SMX may use combination drug . 6.1 Rituximab acceptable maintenance agent last dose give least one month prior enrollment additional dos plan ) duration study ( month 6 visit early termination ) . If patient receive rituximab prescribe another maintenance agent , patient eligible plan treat physician change dose maintenance ( safety purposes/toxicity ) duration study ( month 6 visit early termination ) . 6.2 If patient regularly take trimethoprim/sulfamethoxazole dose patient eligible plan treat physician change dose enrollment ( dose reduction discontinuation safety purposes/toxicity ) duration study . 1 . Comorbid condition moderate likelihood require course prednisone within one year enrollment ( e.g . chronic obstructive pulmonary disease ( COPD ) , asthma , adrenal insufficiency ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Granulomatosis polyangiitis</keyword>
	<keyword>Wegener 's granulomatosis</keyword>
	<keyword>WG</keyword>
	<keyword>GPA</keyword>
	<keyword>ANCA-Associated Vasculitis</keyword>
	<keyword>AAV</keyword>
	<keyword>Vasculitis</keyword>
	<keyword>Prednisone</keyword>
	<keyword>Glucocorticoid</keyword>
	<keyword>Taper</keyword>
</DOC>